ARHGAP5
Rho GTPase-activating protein 5
Also known as: GFI2, p190-B, p190BRhoGAP, RHG05_HUMAN, RhoGAP5
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13017
- Gene
- ARHGAP5
- Ensembl
- ENSG00000100852
- Chromosome
- 14
- Canonical length
- 1502 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Endoplasmic reticulum,Cytosol
OverviewNCBI Gene
Rho GTPase activating protein 5 negatively regulates RHO GTPases, a family which may mediate cytoskeleton changes by stimulating the hydrolysis of bound GTP. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
1502 residues, UniProt reviewed canonical sequence.
>Q13017|ARHGAP5
1 MMAKNKEPRP PSYTISIVGL SGTEKDKGNC GVGKSCLCNR FVRSKADEYY PEHTSVLSTI
61 DFGGRVVNND HFLYWGDIIQ NSEDGVECKI HVIEQTEFID DQTFLPHRST NLQPYIKRAA
121 ASKLQSAEKL MYICTDQLGL EQDFEQKQMP EGKLNVDGFL LCIDVSQGCN RKFDDQLKFV
181 NNLFVQLSKS KKPVIIAATK CDECVDHYLR EVQAFASNKK NLLVVETSAR FNVNIETCFT
241 ALVQMLDKTR SKPKIIPYLD AYKTQRQLVV TATDKFEKLV QTVRDYHATW KTVSNKLKNH
301 PDYEEYINLE GTRKARNTFS KHIEQLKQEH IRKRREEYIN TLPRAFNTLL PNLEEIEHLN
361 WSEALKLMEK RADFQLCFVV LEKTPWDETD HIDKINDRRI PFDLLSTLEA EKVYQNHVQH
421 LISEKRRVEM KEKFKKTLEK IQFISPGQPW EEVMCFVMED EAYKYITEAD SKEVYGRHQR
481 EIVEKAKEEF QEMLFEHSEL FYDLDLNATP SSDKMSEIHT VLSEEPRYKA LQKLAPDRES
541 LLLKHIGFVY HPTKETCLSG QNCTDIKVEQ LLASSLLQLD HGRLRLYHDS TNIDKVNLFI
601 LGKDGLAQEL ANEIRTQSTD DEYALDGKIY ELDLRPVDAK SPYFLSQLWT AAFKPHGCFC
661 VFNSIESLSF IGEFIGKIRT EASQIRKDKY MANLPFTLIL ANQRDSISKN LPILRHQGQQ
721 LANKLQCPFV DVPAGTYPRK FNETQIKQAL RGVLESVKHN LDVVSPIPAN KDLSEADLRI
781 VMCAMCGDPF SVDLILSPFL DSHSCSAAQA GQNNSLMLDK IIGEKRRRIQ ITILSYHSSI
841 GVRKDELVHG YILVYSAKRK ASMGMLRAFL SEVQDTIPVQ LVAVTDSQAD FFENEAIKEL
901 MTEGEHIATE ITAKFTALYS LSQYHRQTEV FTLFFSDVLE KKNMIENSYL SDNTRESTHQ
961 SEDVFLPSPR DCFPYNNYPD SDDDTEAPPP YSPIGDDVQL LPTPSDRSRY RLDLEGNEYP
1021 IHSTPNCHDH ERNHKVPPPI KPKPVVPKTN VKKLDPNLLK TIEAGIGKNP RKQTSRVPLA
1081 HPEDMDPSDN YAEPIDTIFK QKGYSDEIYV VPDDSQNRIK IRNSFVNNTQ GDEENGFSDR
1141 TSKSHGERRP SKYKYKSKTL FSKAKSYYRR THSDASDDEA FTTSKTKRKG RHRGSEEDPL
1201 LSPVETWKGG IDNPAITSDQ ELDDKKMKKK THKVKEDKKQ KKKTKNFNPP TRRNWESNYF
1261 GMPLQDLVTA EKPIPLFVEK CVEFIEDTGL CTEGLYRVSG NKTDQDNIQK QFDQDHNINL
1321 VSMEVTVNAV AGALKAFFAD LPDPLIPYSL HPELLEAAKI PDKTERLHAL KEIVKKFHPV
1381 NYDVFRYVIT HLNRVSQQHK INLMTADNLS ICFWPTLMRP DFENREFLST TKIHQSVVET
1441 FIQQCQFFFY NGEIVETTNI VAPPPPSNPG QLVEPMVPLQ LPPPLQPQLI QPQLQTDPLG
1501 IILocalizationUniProt · AlphaFold · HPA
Whether an antibody against ARHGAP5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.37
- Highest tissue expression
- 64 nTPM
Expression across tissuesHPA
Tissue
- thyroid gland: 64 nTPM
- esophagus: 63 nTPM
- heart muscle: 59 nTPM
- salivary gland: 56 nTPM
- retina: 54 nTPM
- cerebral cortex: 49 nTPM
Single-cell type
- esophageal apical cells: 717 nCPM
- bergmann glia: 489 nCPM
- astrocytes: 449 nCPM
- lacrimal acinar cells: 440 nCPM
- ocular epithelial cells: 437 nCPM
- ependymal cells: 430 nCPM
Immune cell
- plasmacytoid DC: 7.7 nTPM
- memory B-cell: 6.2 nTPM
- NK-cell: 5.9 nTPM
- naive CD4 T-cell: 5.8 nTPM
- memory CD4 T-cell: 5.6 nTPM
- myeloid DC: 5.4 nTPM
Brain region
- white matter: 237 nTPM
- cerebellum: 213 nTPM
- amygdala: 190 nTPM
- basal ganglia: 190 nTPM
- hypothalamus: 190 nTPM
- midbrain: 188 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ARHGAP5.
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 167 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.26
- gnomAD pLI
- 1
- gnomAD missense Z
- 2.21
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell adhesion
- epithelial cell migration
- mammary gland development
- positive regulation of epithelial cell migration
- positive regulation of mesenchymal cell proliferation
- regulation of cell size
- regulation of small GTPase mediated signal transduction
- Rho protein signal transduction
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Rho GTPase-activating protein domain
- FF domain
- Rho GTPase activation protein
- P-loop containing nucleoside triphosphate hydrolase
- Rho GTPase-activating protein, FF domain
- FF domain superfamily
- Rho GTPase-activating protein, pG2 domain
- Rho GTPase-activating protein, pG1 domain
- Rho GTPase-activating protein, pG1 and pG2 domain
- Rho GTPase-activating domain-containing protein
- Rho GTPase-activating protein 35-like, FF domain
- RhoGAP domain
- FF domain
- p190-A and -B Rho GAPs FF domain
- p190RhoGAP, pG1 and pG2 domains
- Rho GTPase-activating protein 35-like, FF domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ARHGAP5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ARHGAP5 as an antibody target. Whether an autoantibody or antibody against ARHGAP5 could matter depends on whether native ARHGAP5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ARHGAP5 is annotated at the cell surface, where native ARHGAP5 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ARHGAP5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...